Stephen Schuster, MD, discusses findings from follow-up of the phase 2 ELARA study presented at the 2023 ASH Annual Meeting.
Stephen J. Schuster, MD
Advertisement
Stephen J. Schuster, MD is the director of the lymphoma program, director of lymphoma rranslational research, and the Robert and Margarita Louis-Dreyfus Professor in Chronic Lymphocytic Leukemia and Lymphoma Clinical Care and Research at Penn Medicine.
Articles by Stephen J. Schuster, MD
Stephen J. Schuster, MD, discusses tisagenlecleucel in adult patients with relapsed/refractory follicular lymphoma in the phase 2 Elara trial and the 5-year follow-up of a smaller CAR T-cell trial.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
4
Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera
5